癌症生物治療市場規模、佔有率、成長分析，按產品、按癌症類型、按階段、按給藥途徑、按分銷管道、按最終用戶、按地區 - 行業預測，2025 年至 2032 年

全球癌症生物治療市場規模預計從 2024 年的 912.7 億美元成長至 2032 年的 1,603.7 億美元，到 2023 年將達到 850.6 億美元，預計在預測期內（2025 年）的複合年成長率為 1.2%。 -2032）。

受癌症發生率上升和專科治療中心出現的推動，全球癌症生物治療市場將迎來顯著成長。專家們正在利用奈米技術的力量開發創新的治療方案，為先進的治療和個人化的患者照護鋪平道路。對生物療法日益重視，加上技術的進步，可望改變癌症治療，為全球患者提供更有效、個人化的治療方法。隨著研究的進步和創新解決方案的出現，市場將大幅擴張並加強對這種毀滅性疾病的持續鬥爭。技術創新與不斷成長的患者需求相結合，為該領域在不久的將來帶來了前所未有的機會。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 專利分析

癌症生物治療市場規模（按產品）

• 市場概況
• 單株抗體（MAB）
  • 裸露的MAB
  • 共軛單株抗體
  • 雙特異性MAB
• 疫苗
  • 預防疫苗
  • 治療性疫苗
• 癌症生長抑制劑
  • 蛋白酪氨酸激酶抑制劑 (TKI)
  • 蛋白酶體抑制劑 (PI)
  • mTOR 抑制劑
• 血球生長因子（BCGF）
  • 來諾司亭
  • Filgrastim
• 細胞激素
  • 干擾素
  • 白細胞介素

癌症生物治療市場規模（按癌症類型）

• 市場概況
• 乳癌
• 肺癌
• 大腸直腸癌
• 攝護腺癌

癌症生物治療市場規模（按階段）

• 市場概況
• 第一階段
• 第二階段
• 第三階段

按給藥途徑分類的癌症生物治療市場規模

• 市場概況
• 口服
• 注射

癌症生物治療市場規模（按分銷管道）

• 市場概況
• 專門癌症治療中心
• 醫院和診所
• 零售藥局

癌症生物治療市場規模（按最終用戶分類）

• 市場概況
• 醫院
• 居家護理
• 專業中心
• 其他

癌症生物治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• AstraZeneca（United Kingdom）
• Pfizer（United States）
• Bristol Myers Squibb（United States）
• Novartis（Switzerland）
• Merck & Co.（United States）
• Roche Holding AG（Switzerland）
• Amgen Inc.（United States）
• Gilead Sciences（United States）
• Eli Lilly and Company（United States）
• Johnson & Johnson（United States）
• Sanofi（France）
• GlaxoSmithKline（United Kingdom）
• Takeda Pharmaceutical Company（Japan）
• Biogen Inc.（United States）
• Regeneron Pharmaceuticals（United States）
• Moderna Inc.（United States）
• BioNTech SE（Germany）
• Incyte Corporation（United States）
• Exelixis, Inc.（United States）

結論和建議

Global Cancer Biological Therapy Market size was valued at USD 85.06 billion in 2023 and is poised to grow from USD 91.27 billion in 2024 to USD 160.37 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global cancer biological therapy market is set for remarkable growth, fueled by the increasing incidence of cancer and the emergence of specialized treatment facilities. Experts are harnessing the power of nanotechnology to develop innovative therapeutic solutions, paving the way for advanced treatments and personalized patient care. The heightened emphasis on biological therapies, combined with technological advancements, is expected to transform cancer care, enabling more effective and tailored treatment options for patients worldwide. As research progresses and innovative solutions emerge, the market is poised for extraordinary expansion, enhancing the ongoing battle against this devastating disease. This convergence of innovation and growing patient needs positions the sector for unprecedented opportunities in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Biological Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Biological Therapy Market Segmental Analysis

Global Cancer Biological Therapy Market is segmented by Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users and region. Based on Product, the market is segmented into Monoclonal antibodies (MAB), Vaccines, Cancer growth blockers, Blood cell growth factors (BCGF) and Cytokines. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer. Based on Phases, the market is segmented into Phase I, Phases II and Phases III. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Specialized Cancer Treatment Centers, Hospitals & Clinics and Retail Pharmacies. Based on End-Users, the market is segmented into Hospitals, Homecare, Speciality Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Biological Therapy Market

One of the primary factors driving the global cancer biological therapy market is the rising incidence of cancer cases across the globe. Recent statistics from the American Cancer Society indicate a concerning increase in Small Cell Lung Cancer (SCLC), predominantly affecting individuals aged 60 to 80. With an estimated annual death toll of about 30,000 from SCLC and lung cancer being the second most common type in both genders-resulting in 1.59 million fatalities as of 2012 per the World Health Organization-these sobering numbers highlight the urgent need for innovative cancer treatments. Consequently, there is a growing demand for cancer biological therapies to effectively combat this escalating health crisis.

Restraints in the Global Cancer Biological Therapy Market

One notable restraint in the Global Cancer Biological Therapy market is the high cost associated with cancer treatment options. The substantial expenses related to these therapies create a significant barrier for many patients, particularly those in rural regions who may struggle to access the necessary funds. This financial strain limits the ability of a large portion of the population to afford essential treatments, thus impeding overall market growth. As a result, the prohibitive pricing of cancer biological therapies remains a critical challenge that needs to be addressed to enhance accessibility and improve patient outcomes in the healthcare system.

Market Trends of the Global Cancer Biological Therapy Market

The global cancer biological therapy market is witnessing a prominent trend towards personalized and targeted therapies, driven by advancements in genomics and molecular biology. As researchers gain deeper insights into the unique genetic and molecular characteristics of various tumors, there is a growing demand for biologic treatments tailored to the specific genetic abnormalities or biomarkers present in patients' cancer cells. This focus on customization enhances treatment efficacy, minimizes adverse effects, and improves overall patient outcomes. By efficiently targeting the molecular underpinnings of tumors, these innovative therapies are transforming oncology, leading to significant market growth as healthcare systems increasingly adopt personalized approaches to cancer treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Patent Analysis

Global Cancer Biological Therapy Market Size by Product & CAGR (2025-2032)

• Market Overview
• Monoclonal antibodies (MAB)
  • Naked MAB
  • Conjugated MAB
  • Bispecific MAB
• Vaccines
  • Preventive vaccines
  • Therapeutic vaccines
• Cancer growth blockers
  • Tyrosine kinase inhibitors (TKI)
  • Proteasome inhibitors (PI)
  • mTOR inhibitors
• Blood cell growth factors (BCGF)
  • Lenograstim
  • Filgrastim
• Cytokines
  • Interferons
  • Interleukins

Global Cancer Biological Therapy Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

Global Cancer Biological Therapy Market Size by Phases & CAGR (2025-2032)

• Market Overview
• Phase I
• Phases II
• Phases III

Global Cancer Biological Therapy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Cancer Biological Therapy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Specialized Cancer Treatment Centers
• Hospitals & Clinics
• Retail Pharmacies

Global Cancer Biological Therapy Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Speciality Centres
• Others

Global Cancer Biological Therapy Market Size & CAGR (2025-2032)

• North America (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • US
  • Canada
• Europe (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Cancer Type, Phases, Route of Administration, Distribution Channel, End-Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations